In silico and saturation transfer difference NMR approaches to unravel the binding mode of an andrographolide derivative to K-Ras oncoprotein

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1. Shaw AT, Winslow MM, Magendantz M et al. Selective killing of K-Ras mutant cancer cells by small molecule inducers of oxidative stress. Proc. Natl Acad. Sci. USA 108(21), 8773–8778 (2011).
  Medline CASGoogle Scholar
• 2. Maurer T, Garrenton LS, Oh A et al. Small-molecule ligands bind to a distinct pocket in Ras and inhibit SOS-mediated nucleotide exchange activity. Proc. Natl Acad. Sci. USA 109(14), 5299–5304 (2012). • Demonstrates a similar binding pocket on K-Ras mutant as discovered in the present study.
  Medline CASGoogle Scholar
• 3. Prior IA, Lewis PD, Mattos CA. Comprehensive survey of Ras mutations in cancer. Cancer Res. 72(10), 2457–2467 (2012).
  Medline CASGoogle Scholar
• 4. Wennerberg K, Rossman KL, Der CJ. The Ras superfamily at a glance. J. Cell Sci. 118(Pt 5), 843–846 (2005).
  Medline CASGoogle Scholar
• 5. Shima F, Yoshikawa Y, Ye M et al. In silico discovery of small-molecule Ras inhibitors that display antitumor activity by blocking the Ras-effector interaction. Proc. Natl Acad. Sci. USA 110(20), 8182–8187 (2013). • Demonstrates a similar binding pocket on K-Ras mutant as discovered in the present study.
  Medline CASGoogle Scholar
• 6. Kapoor A, Travesset A. Differential dynamics of RAS isoforms in GDP- and GTP-bound states. Proteins 83(6), 1091–1106 (2015).
  Medline CASGoogle Scholar
• 7. Collins MA, Pasca di Magliano M. KRAS as a key oncogene and therapeutic target in pancreatic cancer. Front. Physiol. 4, 407 (2014).
  MedlineGoogle Scholar
• 8. Mascaux C, Iannino N, Martin B et al. The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis. Br. J. Cancer 92(1), 131–139 (2005).
  Medline CASGoogle Scholar
• 9. Pao W, Wang TY, Riely GJ et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med. 2(1), e17 (2005).
  MedlineGoogle Scholar
• 10. Massarelli E, Varella-Garcia M, Tang X et al. KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. Clin. Cancer Res. 13(10), 2890–2896 (2007).
  Medline CASGoogle Scholar
• 11. Sun Q, Burke JP, Phan J et al. Discovery of small molecules that bind to K-Ras and inhibit SOS-mediated activation. Angew. Chem. Int. Ed. Engl. 51(25), 6140–6143 (2012). • Demonstrates a similar binding pocket on K-Ras mutant as discovered in the present study.
  Medline CASGoogle Scholar
• 12. Jančik S, Drábek J, Radzioch D, Hajdúch M. Clinical relevance of KRAS in human cancers. Biomed. Res. Int. 2010, 150960 (2010).
  Google Scholar
• 13. Grant BJ, Lukman S, Hocker HJ et al. Novel allosteric sites on Ras for lead generation. PLoS ONE 6, e25711 (2011). • Demonstrated similar binding pockets on K-Ras mutant as discovered in the present study.
  Medline CASGoogle Scholar
• 14. Hocker HJ, Cho K, Chen CK et al. Andrographolide derivatives inhibit guanine nucleotide exchange and abrogate oncogenic Ras function. Proc. Natl Acad. Sci. USA 110(25), 10201–10206 (2013). •• Demonstrates similar binding pockets on K-Ras mutant as discovered in the present study and reported the anticancer activity of benzylidene derivatives of andrographolide.
  Medline CASGoogle Scholar
• 15. Stanslas J, Liew PS, Iftikhar N et al. Potential of AG in the treatment of breast cancer. Eur. J. Cancer 37(6), 169 (2001).
  Google Scholar
• 16. Rajagopal S, Kumar RA, Deevi DS, Satyanarayana C, Rajagopalan R. Andrographolide, a potential cancer therapeutic agent isolated from Andrographis paniculata. J. Exp. Ther. Oncol. 3(3), 147–158 (2003).
  Medline CASGoogle Scholar
• 17. Ponnam D, Vadithe LN, Yadav DK et al. Synthesis and evaluation of anticancer activity of novel andrographolide derivatives. Med. Chem. Commun. 6(5), 898–904 (2015).
  Google Scholar
• 18. Mokenapelli S, Yerrabelli JR, Das N, Roy P, Chitneni PR. Synthesis and cytotoxicity of novel 14α-O-(andrographolide-3-subsitutedisoxazole-5-carboxylate) derivatives. Nat. Prod. Res. 34, 1–7 (2020).
  MedlineGoogle Scholar
• 19. Jada SR, Hamzah AS, Lajis NH, Saad MS, Stevens MFG, Stanslas J. Semisynthesis and cytotoxic activities of andrographolide analogues. J. Enzyme Inhib. Med. Chem. 21(2), 145–155 (2006).
  Medline CASGoogle Scholar
• 20. Jada SR, Matthews C, Saad MS et al. Benzylidene derivatives of andrographolide inhibit growth of breast and colon cancer cells in vitro by inducing G1 cell cycle arrest and apoptosis. Br. J. Pharmacol. 155(5), 641–654 (2008). • Demonstrates the inhibitory activity of benzylidene derivatives of andrographolide (SRJ09 and SRJ23) particularly in cancer cells bearing mutant Ras.
  Medline CASGoogle Scholar
• 21. Rosnizek IC, Spoerner M, Harsch T et al. Metal-bis(2-picolyl)-amine complexes as state 1(T) inhibitors of activated Ras protein. Angew. Chem. Int. Ed. Engl. 51(42), 10647–10651 (2012).
  MedlineGoogle Scholar
• 22. Kessler D, Gmachi M, Mantoulidis A et al. Drugging an undruggable pocket on KRAS. Proc. Natl Acad. Sci. USA 116(32), 15823–15829 (2019).
  Medline CASGoogle Scholar
• 23. Marín-Ramos NI, Piñar C, Vázquez-Villa H et al. Development of a nucleotide exchange inhibitor that impairs Ras oncogenic signaling. Chem. Eur. J. 23(7), 1676–1685 (2017).
  Medline CASGoogle Scholar
• 24. Mayer M, Meyer B. Group epitope mapping by saturation transfer difference NMR to identify segments of a ligand in direct contact with a protein receptor. J. Am. Chem. Soc. 123(25), 6108–6117 (2001).
  Medline CASGoogle Scholar
• 25. Schrödinger Release 2015-1. Maestro, Schrödinger, LLC. NY, USA (2015).
  Google Scholar
• 26. Glide version 6.6. Schrödinger, LLC. NY, USA (2015).
  Google Scholar
• 27. SiteMap version 3.4. Schrödinger, LLC. NY, USA (2015).
  Google Scholar
• 28. LigPrep version 3.3. Schrödinger, LLC. NY, USA (2015).
  Google Scholar
• 29. Prime version 3.9. Schrödinger, LLC. NY, USA (2015).
  Google Scholar
• 30. Schrödinger. Schrödinger KnowledgeBase, MacroModel contains a variety of force fields. Which is best for my purpose? www.schrodinger.com/kb/1266 (Accessed 14 March, 2016).
  Google Scholar
• 31. Desmond Molecular Dynamics System version 4.1. D.E. Shaw Research, Schrödinger, LLC. NY, USA (2015).
  Google Scholar
• 32. Maestro-Desmond Interoperability Tools version 4.1. Maestro, Schrödinger, LLC. NY, USA (2015)
  Google Scholar
• 33. Ostrem JM, Peters U, Sos ML, Wells JA, Shokat KM. K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature 503, 548–551 (2013).
  Medline CASGoogle Scholar
• 34. Hunter JC, Gurbani D, Ficarro SB et al. In situ selectivity profiling and crystal structure of SML-8-73-1 and active site inhibitor of oncogenic K-Ras G12C. Proc. Natl Acad. Sci. USA 111(24), 8895–8900 (2014). • Demonstrates a similar binding pocket on K-Ras mutant as discovered in the present study.
  Medline CASGoogle Scholar
• 35. Friesner RA, Banks JL, Murphy RB et al. Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J. Med. Chem. 47(7), 1739–1749 (2004).
  Medline CASGoogle Scholar
• 36. Halgren T. New method for fast and accurate binding-site identification and analysis. Chem. Biol. Drug Des. 69(2), 146–148 (2007).
  Medline CASGoogle Scholar
• 37. Friesner RA, Murphy RB, Repasky MP et al. Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein–ligand complexes. J. Med. Chem. 49(21), 6177–6196 (2006).
  Medline CASGoogle Scholar
• 38. Genheden S, Ryde U. The MM/PBSA and MM/GBSA methods to estimate ligand-binding affinities. Expert Opin. Drug Discov. 10(5), 449–461 (2015).
  Medline CASGoogle Scholar
• 39. Deb PK, Mailavaram R, Chandrasekaran B et al. Synthesis, adenosine receptor binding and molecular modeling studies of novel thieno[2,3-d]pyrimidine derivatives. Chem. Biol. Drug Des. 91(4), 962–969 (2018).
  Medline CASGoogle Scholar
• 40. Uline MJ, Corti DS. Molecular dynamics at constant pressure: allowing the system to control volume fluctuations via a “shell” particle. Entropy 15(9), 3941–3969 (2013).
  Google Scholar
• 41. Tuckerman M, Berne BJ, Rossi A. Molecular dynamics algorithm for multiple time scales: systems with disparate masses. J. Chem. Phys. 94(2), 1465–1469 (1990).
  Google Scholar
• 42. Tuckerman M, Berne BJ, Martyna GJ. Reversible multiple time scale molecular dynamics. J. Chem. Phys. 97(3), 1990–2001 (1992).
  CASGoogle Scholar
• 43. Tan MS, Teh YH, Ho KL, Stanslas J. An application of pET SUMO protein expression system in Escherichia coli: cloning, expression, purification and characterisation of native Kras4B^G12V oncoprotein. Protein J. 39, 54–61 (2020). • Discusses the method of producing GDP-loaded K-RasG12V protein that was used in the present study.
  Medline CASGoogle Scholar
• 44. Seeburg PH, Colby WW, Capon DJ, Goeddel DV, Levinson AD. Biological properties of human c-Ha-Ras1 genes mutated at codon 12. Nature 312(5989), 71–75 (1984).
  Medline CASGoogle Scholar
• 45. Reva B, Antipin Y, Sander C. Predicting the functional impact of protein mutations: application to cancer genomics. Nucleic Acids Res. 39(17), e118 (2011).
  Medline CASGoogle Scholar
• 46. Ghattas MA, Raslan N, Sadeq A, Al Sorkhy M, Atatreh N. Druggability analysis and classification of protein tyrosine phosphatase active sites. Drug Des. Devel. Ther. 10, 3197–3209 (2016).
  Medline CASGoogle Scholar
• 47. Prakash P, Hancock JF, Gorfe AA. Binding hotspots on K-Ras: consensus ligand binding sites and other reactive regions from probe-based molecular dynamics analysis. Proteins 83(5), 898–909 (2015).
  Medline CASGoogle Scholar
• 48. Scheffzek K, Ahmadian MR, Kabsch W et al. The Ras–RasGAP complex: structural basis for GTPase activation and its loss in oncogenic Ras mutants. Science 277(5324), 333–339 (1997).
  Medline CASGoogle Scholar
• 49. Boriack-Sjodin PA, Margarit SM, Bar-Sagi D, Kuriyan J. The structural basis of the activation of Ras by SOS. Nature 394(6691), 337–343 (1998).
  Medline CASGoogle Scholar
• 50. Lim JCW, Chan TK, Ng DS, Sagineedu SR, Stanslas J, Wong WS. Andrographolide and its analogues: versatile bioactive molecules for combating inflammation and cancer. Clin. Exp. Pharmacol. Physiol. 39(3), 300–310 (2012).
  Medline CASGoogle Scholar
• 51. Ferreira LG, dos Santos RN, Oliva G, Andricopulo AD. Molecular docking and structure-based drug design strategies. Molecules 20(7) 13384–13421 (2015).
  Medline CASGoogle Scholar
• 52. Hillig RC, Sautier B, Schroeder J et al. Discovery of potent SOS1 inhibitors that block RAS activation via disruption of the RAS–SOS1 interaction. Proc. Natl Acad. Sci. USA 116(7), 2551–2560 (2019).
  Medline CASGoogle Scholar
• 53. Hopkins AL, Groom CR. The druggable genome. Nat. Rev. Drug Discov. 1(9), 727–730 (2002).
  Medline CASGoogle Scholar
• 54. Sugiki T, Furuita K, Fujiwara T, Kojima C. Current NMR techniques for structure-based drug discovery. Molecules 23, 148 (2018).
  Google Scholar
• 55. Gysin S, Salt M, Young A, McCormick F. Therapeutic strategies for targeting Ras proteins. Genes Cancer. 2(3), 359–372 (2011).
  Medline CASGoogle Scholar
• 56. Traut TW. Physiological concentration of purines and pyrimidines. Mol. Cell. Biochem. 140(1), 1–22 (1994).
  Medline CASGoogle Scholar
• 57. Stanley RJ, Thomas GMH. Activation of G proteins by guanine nucleotide exchange factors relies on GTPase activity. PLoS ONE 11(3), e0151861 (2016).
  MedlineGoogle Scholar
• 58. Wang YS, Liu D, Wyss DF. Competition STD NMR for the detection of high-affinity ligands and NMR-based screening. Magn. Reson. Chem. 42(6), 485–489 (2004).
  Medline CASGoogle Scholar
• 59. Sprangers R, Velyvis A, Kay LE. Solution NMR of supramolecular complexes: providing new insights into function. Nat. Methods. 4(9), 697–703 (2007).
  Medline CASGoogle Scholar
• 60. Venkitakrishnan RP, Benard O, Max M, Markley JL, Assadi-Porter FM. Use of NMR saturation transfer difference spectroscopy to study ligand binding to membrane proteins. Methods Mol. Biol. 914, 47–63 (2012).
  Medline CASGoogle Scholar
• 61. Skinner AL, Laurence JS. High-field solution NMR spectroscopy as a tool for assessing protein interactions with small molecule ligands. J. Pharm. Sci. 97(11), 4670–4695 (2008).
  Medline CASGoogle Scholar
• 62. Mulder FA, Hon B, Muhandiram DR, Dahlquist FW, Kay LE. Flexibility and ligand exchange in a buried cavity mutant of T4 lysozyme studied by multinuclear NMR. Biochemistry 39(41), 12614–12622 (2000).
  Medline CASGoogle Scholar
• 63. Macha MA, Batra SK, Ganti AK. Profile of vismodegib and its potential in the treatment of advanced basal cell carcinoma. Cancer Manag. Res. 5, 197–203 (2013).
  MedlineGoogle Scholar
• 64. Drews J. Drug discovery: a historical perspective. Science 287(5460), 1960–1964 (2000).
  Medline CASGoogle Scholar
• 65. Meyer B, Peters T. NMR spectroscopy techniques for screening and identifying ligand binding to protein receptors. Angew. Chem. Int. Ed. Engl. 42(8), 864–890 (2003).
  Medline CASGoogle Scholar
• 66. Muñoz-García JC, Álvarez JA, Nieto Mesa PM. NMR for structural glycoscience. Part II. ligand based NMR spectroscopy for binding studies. http://glycopedia.eu/e-chapters/NMR-for-Structural-Glycoscience-35/THe-Authors-126
  Google Scholar
• 67. Kotar A, Tomašič T, Živković ML, Jug G, Plavec J, Anderluh M. STD NMR and molecular modelling insights into interaction of novel mannose-based ligands with DC-SIGN. Org. Biomol. Chem. 14(3), 862–875 (2016).
  Medline CASGoogle Scholar
• 68. van der Merwe PA. Surface plasmon resonance. In: Protein-Ligand Interactions: Hydrodynamics and Calorimetry. Harding SEChowdhry BZ (Eds). Oxford University Press, Oxford, UK, 137–170 (2001).
  Google Scholar
• 69. Pons J, Evrard-Todeschi N, Bertho G et al. Transfer-NMR and docking studies identify the binding of the peptide derived from activating transcription factor 4 to protein ubiquitin ligase beta-TrCP. Competition STD-NMR with beta-catenin. Biochemistry 47(1), 14–29 (2008).
  Medline CASGoogle Scholar